<DOC>
	<DOCNO>NCT00978029</DOCNO>
	<brief_summary>The purpose study assess safety tolerability ragweed allergy immunotherapy tablet ( AIT ) administer sublingually ( under-the tongue ) subject 50 year age old ragweed-induced rhinoconjunctivitis , without asthma .</brief_summary>
	<brief_title>Safety Study Ragweed Allergy Immunotherapy Tablet Subjects 50 Years Age Older ( Study P06081 )</brief_title>
	<detailed_description />
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Conjunctivitis</mesh_term>
	<criteria>Subject must 50 year age old , either sex , race/ethnicity . Subject must clinical history ragweedinduced allergic rhinoconjunctivitis without asthma . Subject must positive skin prick test response Ambrosia artemisiifolia Screening Visit Subject must force expiratory volume 1 second ( FEV1 ) least 70 % predict value Screening Visit Randomization . A subject 's clinical laboratory test , electrocardiogram ( ECG ) vital sign conduct Screening Visit must within normal limit clinically acceptable investigator . Subject asthma require inhaled corticosteroid treatment asthma study period . Subject require antiallergy medication time period randomization study completion . Subject receive immunosuppressive treatment within 3 month prior Screening Visit ( except steroid allergic asthma symptom ) . Subject history anaphylaxis cardiorespiratory symptom . Subject history chronic urticaria angioedema . Subject current severe atopic dermatitis . Female subject breastfeeding , pregnant , intend become pregnant . Subject history allergy , hypersensitivity intolerance ingredient investigational medicinal product ( IMPs ) ( except Ambrosia artemisiifolia ) , selfinjectable epinephrine . Subject history selfinjectable epinephrine use .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>immunotherapy</keyword>
</DOC>